Sarah Appelbaum is a Manager in the Life Sciences Consulting Group in the Litigation Department of Paul Hastings, based in the firm's New York office. Ms. Appelbaum has experience in supporting multinational Pharmaceutical corporations in implementing strategic operating model enhancements and specialty projects. Her experience within Life Sciences spans cross-functionally to include Finance, Medical Affairs, Commercial, and Corporate Affairs. She has executed a number of high-impact initiatives, beginning with the strategic ideation phase, then guiding clients through implementation to ultimately deliver value across the organization. Sarah specializes in corporate strategy/specialty projects, program management, product launch, and lifecycle planning.
Ms. Appelbaum provides advisory services and is not a licensed attorney.
New York University: Bachelor of Science, Chemical and Bimolecular Engineering
New York University: Master of Science, Management of Technology
Volunteer Middle School Tutor at KIPP Charter Schools
In Life Sciences
Oversaw philanthropic grants program, awarding $1.1M to 14 organizations in 10 countries to support projects aimed at closing gaps in Lung Cancer patient experiences around the world. Defined the end-to-end grant strategy, including application criteria, award categories, and the review of committee roles and responsibilities to secure buy-in and sponsorship from leadership.
Executed strategic initiative to build awareness of lung cancer globally by implementing 25+ targeted initiatives across three workstreams, including investment into digital solutions to ultimately achieve the goal of doubling five-year survival and eliminating lung cancer as a leading cause of death. Secured three external partnerships with established industry leaders to form the Lung Ambition Alliance broadening the reach of the program from U.S. and European-based stakeholders from across the lung cancer ecosystem.
Led KOL identification and mapping exercise to identifying 30 key opinion leaders (KOL), across five markets to advise the client organization on the value of surrogate endpoints in novel pricing schemas.
Led engagement to develop Integrated Medical Affairs Launch Strategy to support accelerated FDA approval of priority and lifecycle planning across medical sub-functions (MedInfo, MedComms, Field Medical, Evidence Generation, and Stakeholder Engagement). Engagement included chartering a Compassionate Use Program in the United States to ensure access to innovative treatment prior to U.S. Launch.
Executed legal entity alignment in preparation for future pharmaceutical client divestiture, managing budget of $140M across 12 functions and reducing program budget by an average of $9M per quarter by redefining existing budget refresh processes and identifying inefficiencies across functional activities.
Supported execution of finance operating model transformation focusing on labor arbitrage, investment in technology, and standardization of processes to achieve net savings of $24M over 2 years.